SEC Form 4 · accession 0001209191-18-041074
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian F Smith
Officer — EVP, COO
Period of report
Jun 29, 2018
Accepted (ET)
Jul 3, 2018 · 4:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2018 | M | 23,375 | $131.89 | A | 70,074 | D | |
| Common StockF2,F3 | Jun 29, 2018 | S | 4,741 | $165.22 | D | 65,333 | D | |
| Common StockF3,F4 | Jun 29, 2018 | S | 18,634 | $166.57 | D | 46,699 | D | |
| Common Stock | holding | — | — | — | 5,306 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $131.89 | Jun 29, 2018 | M | 23,375 | D | — | Jul 20, 2025 | Common Stock | 23,375 | 10,625 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89).
- F3Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67).
- F5The option vests in 16 quarterly installments from 7/21/2015.